EPISODE · Oct 31, 2015 · 51 MIN
Regenerative Medicine And Healthcare Risks
from Risk Roundup
Deven Patel, CEO, President & Co-founder at Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A participates in Risk Roundup to discuss Regenerative Medicine and Healthcare Risks. Regenerative Medicine and Healthcare Risks While a big-data revolution is underway in health care, there is also another silent revolution brewing in the healthcare industry in the form of Regenerative Medicine. Today, Regenerative Medicine: Stem cell research and therapy do not only involve questions of what we can do to manage the critical security risks facing the healthcare industry but also bring us critical questions about what we should do to how we should do it. As Stem cells and their use in Regenerative medicine get popular and have been talked about a lot lately, time is now to talk about Regenerative Medicine and Healthcare risks! For more please watch the Risk Roundup Webcast or hear the Risk Roundup Podcast About the Guest Deven Patel, CEO, President & Co-founder at Global Institute of Stem Cell Therapy and Research (GIOSTAR) About Risk Group Risk Group is a leading strategic security risk research and reporting organization. Copyright Risk Group LLC. All Rights Reserved The post Regenerative Medicine And Healthcare Risks appeared first on Risk Group.
Embed this episode
NOW PLAYING
Regenerative Medicine And Healthcare Risks
No transcript for this episode yet
Similar Episodes
No similar episodes found.